🇺🇸 FDA
Patent

US 10314790

Sustained-release formulations of topiramate

granted A61KA61K31/357A61K31/7048

Quick answer

US patent 10314790 (Sustained-release formulations of topiramate) held by Supernus Pharmaceuticals, Inc. expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Supernus Pharmaceuticals, Inc.
Grant date
Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/357, A61K31/7048, A61K45/06, A61K47/6951